Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16221439 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7088557 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9236812 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL30531901 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL9236815 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802600 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL2770760 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL2770762 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL22618509 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16221413 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108627647-B | Detection and quantification method of post-translational modification proteomics | 四川大学 | 2020-06-19 | — | — | CN | claimed |
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | SYNERGIA LIFE SCIENCES PVT. LTD. (IN) | 2026-01-15 | — | — | US | disclosed |
| EP-4554925-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | Synergia Life Sciences Pvt. Ltd (IN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119486994-A | Method for synthesizing vitamin K2 | 辛纳吉亚生命科学私人有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024013633-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | SYNERGIA LIFE SCIENCES PVT. LTD. (IN) | 2024-01-18 | — | — | WO | disclosed |
| CN-117017874-B | Anti-wrinkle tightening face cream and preparation method thereof | 铂臻(广州)生物科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-117017874-A | Anti-wrinkle tightening face cream and preparation method thereof | 铂臻(广州)生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-108627647-B | Detection and quantification method of post-translational modification proteomics | 四川大学 | 2020-06-19 | — | — | CN | disclosed |
| US-20200033361-A1 | Detection and Quantitation Method for Proteomics of Post-Translational Modifications | SICHUAN UNIVERSITY (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2992910-A1 | ADHESION PREVENTING AGENT | Farnex Incorporated (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-20090192332-A1 | Method for Preparing Isoprenyl Cysteine Compounds and Analogs Thereof | RAPOLE KESHAVA | 2009-07-30 | — | — | US | disclosed |
| WO-2009094534-A1 | IMPROVED METHOD FOR PREPARING ISOPRENYL CYSTEINE COMPOUNDS AND ANALOGS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| CN-101139272-A | Method for synthesizing vitamin K2 | NANJING RHINE PHARM TECHNOLOGY (CN) | 2008-03-12 | — | — | CN | disclosed |
| US-20030028054-A1 | SYNTHESIS OF COENZYME Q10 UBIQUINONE | WEST DANIEL DAVID (US) | 2003-02-06 | — | — | US | disclosed |
| US-6506915-B1 | Stereospecific synthesis of optically pure trans (E)isomer of coenzyme Q10 starting from geranyl bromide and 2,3,4,5-tetramethoxytoluene | WEST DANIEL DAVID (US) | 2003-01-14 | — | — | US | disclosed |
| US-5571687-A | TREATING CELLS WITH SPECIFIED COMPOUNDS TO EFFECT EXPRESSION OF MEMBRANE TRANSPORTER | DUKE UNIVERSITY (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1995033847-A1 | MODULATORS OF MULTIDRUG RESISTANCE TRANSPORTERS | DUKE UNIVERSITY (US) | 1995-12-14 | — | — | WO | disclosed |
| US-4116955-A | META-CYCLOPHANE AND A TRANS-TERPENOID, SEPARATION OF ISOMERS | TEIJIN LIMITED (JP) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | PROC, TPRKB, KCNK9 | KMT2A 863/4885MAPT 4009/4885MEN1 300/4885 |
| US-20030028054-A1 | SYNTHESIS OF COENZYME Q10 UBIQUINONE | NDUFB10, NDUFA10, SQLE | KMT2A 4404/4885MAPT 2579/4885MEN1 1690/4885 |
| US-20090192332-A1 | Method for Preparing Isoprenyl Cysteine Compounds and Analogs Thereof | LCAT, LIPA, GPX4 | KMT2A 4327/4885MAPT 4815/4885MEN1 4075/4885 |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | KMT2A 2693/4885MAPT 4116/4885MEN1 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.